GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInvent International AB (OSTO:BINV) » Definitions » 5-Year EBITDA Growth Rate

BioInvent International AB (OSTO:BINV) 5-Year EBITDA Growth Rate : 1.30% (As of Dec. 2024)


View and export this data going back to 2001. Start your Free Trial

What is BioInvent International AB 5-Year EBITDA Growth Rate?

BioInvent International AB's EBITDA per Share for the three months ended in Dec. 2024 was kr-1.84.

During the past 3 years, the average EBITDA Per Share Growth Rate was -9.30% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 1.30% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 15.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of BioInvent International AB was 74.30% per year. The lowest was -198.10% per year. And the median was 13.00% per year.

Competitive Comparison of BioInvent International AB's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, BioInvent International AB's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioInvent International AB's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioInvent International AB's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where BioInvent International AB's 5-Year EBITDA Growth Rate falls into.


;
;

BioInvent International AB 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

BioInvent International AB  (OSTO:BINV) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

BioInvent International AB 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of BioInvent International AB's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

BioInvent International AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInvent International AB (OSTO:BINV) » Definitions » 5-Year EBITDA Growth Rate
Comparable Companies
OSTO:VICO OSTO:HNSA OSTO:EGTX OSTO:GENO OSTO:XSPRAY OSTO:DMYD B OSTO:SYNACT XSAT:HAMLET B OSTO:SANION OSTO:MAGLE VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
0H22:UK BIX0:Germany
Address
Ideongatan 1, Lund, SWE, SE-223 70
Website
https://www.bioinvent.com
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.

BioInvent International AB Headlines

No Headlines